{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:09:00Z","timestamp":1791857340342,"version":"4.3.4"},"reference-count":108,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD), are among the leading causes of disability worldwide and are frequently associated with treatment resistance, functional impairment, and high comorbidity with metabolic dysfunction. Increasing evidence implicates insulin resistance (IR) as a key pathophysiological factor linking metabolic and psychiatric illness. IR is associated with chronic low-grade inflammation, hypothalamic\u2013pituitary\u2013adrenal (HPA) axis dysregulation, impaired neuroplasticity, mitochondrial dysfunction, and altered reward processing mechanisms that may contribute to core depressive features such as anhedonia, cognitive slowing, and emotional dysregulation. These processes are further exacerbated by the metabolic side effects of many psychotropic medications, creating a self-perpetuating cycle that worsens both psychiatric and physical health outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for type 2 diabetes and obesity, have emerged as promising candidates to address this metabolic\u2013psychiatric interface. Beyond improving glycemic control and promoting weight loss, GLP-1 RAs exert central actions relevant to mood disorders, including modulation of dopaminergic reward pathways, enhancement of hippocampal neurogenesis, attenuation of neuroinflammation, and regulation of appetite and energy balance. Preclinical studies demonstrate that GLP-1 RAs reduce microglial activation, promote hippocampal neurogenesis, and normalize stress-induced behavioral changes. Early clinical trials in patients with metabolic disorders suggest improvements in depressive symptoms, quality of life, and cognitive function, with some effects independent of weight loss or glycemic outcomes. Observational evidence also indicates reduced antidepressant use and psychological distress in diabetic and obese populations receiving GLP-1 RAs. While these findings are promising, large randomized controlled trials in primary psychiatric populations are lacking. Key challenges include clarifying dose\u2013response relationships, disentangling central from peripheral effects, and addressing safety and adherence concerns in individuals with comorbid psychiatric conditions. Future research should focus on biomarker-informed stratification, comparative trials with standard treatments, and integration of GLP-1 RAs into multimodal care frameworks. Overall, GLP-1 RAs represent a biologically plausible and clinically relevant approach to bridging metabolic and psychiatric care, with the potential to improve outcomes in patients with mood disorders who carry a high metabolic burden.<\/jats:p>","DOI":"10.3390\/life15091422","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:04:55Z","timestamp":1757505895000},"page":"1422","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8130-4388","authenticated-orcid":false,"given":"Pietro","family":"Carmellini","sequence":"first","affiliation":[{"name":"Department of Molecular and Developmental Medicine, Division of Psychiatry, School of Medicine, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cuomo","sequence":"additional","affiliation":[{"name":"Department of Molecular and Developmental Medicine, Division of Psychiatry, School of Medicine, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Beatrice","family":"Rescalli","sequence":"additional","affiliation":[{"name":"Department of Molecular and Developmental Medicine, Division of Psychiatry, School of Medicine, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5827-0853","authenticated-orcid":false,"given":"Andrea","family":"Fagiolini","sequence":"additional","affiliation":[{"name":"Department of Molecular and Developmental Medicine, Division of Psychiatry, School of Medicine, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"The Lancet Psychiatry (2024). Global Burden of Disease 2021: Mental health messages. Lancet Psychiatry, 11, 573.","DOI":"10.1016\/S2215-0366(24)00222-0"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/YCO.0000000000000905","article-title":"Consolidating evidence on the role of insulin resistance in major depressive disorder","volume":"37","author":"Krupa","year":"2024","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_3","first-page":"394","article-title":"Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry Off. J. World Psychiatr. Assoc. WPA"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Calkin, C., McClelland, C., Cairns, K., Kamintsky, L., and Friedman, A. (2021). Insulin Resistance and Blood-Brain Barrier Dysfunction Underlie Neuroprogression in Bipolar Disorder. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.636174"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1176\/appi.ajp.2021.20101479","article-title":"Incident Major Depressive Disorder Predicted by Three Measures of Insulin Resistance: A Dutch Cohort Study","volume":"178","author":"Watson","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"108877","DOI":"10.1016\/j.neuropharm.2021.108877","article-title":"Peripheral versus central insulin and leptin resistance: Role in metabolic disorders, cognition, and neuropsychiatric diseases","volume":"203","author":"Erichsen","year":"2022","journal-title":"Neuropharmacology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"S\u0103lcudean, A., Bodo, C.-R., Popovici, R.-A., Cozma, M.-M., P\u0103curar, M., Cr\u0103ciun, R.-E., Crisan, A.-I., Enatescu, V.-R., Marinescu, I., and Cimpian, D.-M. (2025). Neuroinflammation\u2014A Crucial Factor in the Pathophysiology of Depression\u2014A Comprehensive Review. Biomolecules, 15.","DOI":"10.3390\/biom15040502"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kim, Y.-K., Kim, O.Y., and Song, J. (2020). Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01270"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Fanelli, G., Bralten, J., Franke, B., Roth Mota, N., Atti, A.R., De Ronchi, D., Monteleone, A.M., Grassi, L., Serretti, A., and Fabbri, C. (2025). Insulin resistance and poorer treatment outcomes in depression: Evidence from UK Biobank primary care data. Br. J. Psychiatry J. Ment. Sci., 1\u201310.","DOI":"10.1192\/bjp.2025.82"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Diz-Chaves, Y., Herrera-P\u00e9rez, S., Gonz\u00e1lez-Mat\u00edas, L.C., Lamas, J.A., and Mallo, F. (2020). Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress. Nutrients, 12.","DOI":"10.3390\/nu12113304"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1399-5448.2009.00606.x","article-title":"Psychological symptoms and insulin sensitivity in adolescents","volume":"11","author":"Shomaker","year":"2010","journal-title":"Pediatr. Diabetes"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Li, K., Li, T., Yang, T., Lin, Y., Liao, Y., and Gan, Z. (2024). Prevalence of insulin resistance and its associated factors in drug-na\u00efve patients with bipolar disorder among Han Chinese population. BMC Psychiatry, 24.","DOI":"10.1186\/s12888-024-05838-5"},{"key":"ref_13","first-page":"1505","article-title":"Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review","volume":"13","author":"Paredes","year":"2023","journal-title":"Eur. J. Investig. Health Psychol. Educ."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.5498\/wjp.v14.i6.767","article-title":"Metabolic complications of psychotropic medications in psychiatric disorders: Emerging role of de novo lipogenesis and therapeutic consideration","volume":"14","author":"Khan","year":"2024","journal-title":"World J. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e70661","DOI":"10.1002\/brb3.70661","article-title":"Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review","volume":"15","author":"Meshkat","year":"2025","journal-title":"Brain Behav."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., and Zhang, Y. (2021). GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.721135"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107415","DOI":"10.1016\/j.psyneuen.2025.107415","article-title":"The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review","volume":"176","author":"Breit","year":"2025","journal-title":"Psychoneuroendocrinology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s40501-024-00331-y","article-title":"The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review","volume":"11","author":"Nicastri","year":"2024","journal-title":"Curr. Treat. Options Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gammoh, O., Qnais, E., Aljabali, A.A.A., Hataet, T., and Alqudah, A. (2025). Metabolic resilience: Liraglutide\u2019s potential in alleviating depressive symptoms. Mol. Biol. Rep., 52.","DOI":"10.1007\/s11033-025-10641-w"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-8587(15)00134-5","article-title":"The link between depression and diabetes: The search for shared mechanisms","volume":"3","author":"Moulton","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Fernandes, B.S., Salagre, E., Enduru, N., Grande, I., Vieta, E., and Zhao, Z. (2022). Insulin resistance in depression: A large meta-analysis of metabolic parameters and variation. Neurosci. Biobehav. Rev., 139.","DOI":"10.1016\/j.neubiorev.2022.104758"},{"key":"ref_23","first-page":"2911","article-title":"GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner","volume":"42","author":"Trammell","year":"2021","journal-title":"Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2337\/db16-0755","article-title":"Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight","volume":"66","author":"Anderberg","year":"2017","journal-title":"Diabetes"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2019.01.016","article-title":"Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression","volume":"315","author":"Hamer","year":"2019","journal-title":"Exp. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhang, X., Du, P., Bai, B., Feng, P., Lian, X., H\u00f6lscher, C., Wang, Y., and Xue, G. (2025). The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson\u2019s disease with diabetes co-morbidity. Front. Neurosci., 19.","DOI":"10.3389\/fnins.2025.1596506"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainresbull.2011.10.004","article-title":"Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases","volume":"87","author":"Smith","year":"2012","journal-title":"Brain Res. Bull."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Al-Roub, A., Al Madhoun, A., Akhter, N., Thomas, R., Miranda, L., Jacob, T., Al-Ozairi, E., Al-Mulla, F., Sindhu, S., and Ahmad, R. (2021). IL-1\u03b2 and TNF\u03b1 Cooperativity in Regulating IL-6 Expression in Adipocytes Depends on CREB Binding and H3K14 Acetylation. Cells, 10.","DOI":"10.3390\/cells10113228"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Liu, Q.K. (2024). Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1431292"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e003218","DOI":"10.1136\/bmjdrc-2022-003218","article-title":"Review of the direct and indirect effects of hyperglycemia on the HPA axis in T2DM and the co-occurrence of depression","volume":"12","author":"Mosili","year":"2024","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11795514221090244","DOI":"10.1177\/11795514221090244","article-title":"Hyperinsulinemia Associated Depression","volume":"15","author":"Sarwar","year":"2022","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41380-018-0017-5","article-title":"Depression and obesity: Evidence of shared biological mechanisms","volume":"24","author":"Milaneschi","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jad.2016.12.059","article-title":"Medical comorbidity in bipolar disorder: The link with metabolic-inflammatory systems","volume":"211","author":"SayuriYamagata","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref_35","first-page":"e549","article-title":"The bidirectional relationship between insulin resistance and psychiatric disorders: Considerations for using HOMA-IR index","volume":"164","author":"Salviati","year":"2013","journal-title":"Clin. Ter."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Starostina, E. (2025). Comorbidity Between Severe Mental Disorders and Metabolic Disease. Comorbidity Between Mental and Physical Disorders, Springer.","DOI":"10.1007\/978-3-031-81802-8_8"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3928\/00485713-20200713-01","article-title":"Metabolic Syndrome in Bipolar Disorder: Review and Management","volume":"50","author":"Regan","year":"2020","journal-title":"Psychiatr. Ann."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/YIC.0000000000000515","article-title":"Type 2 diabetes mellitus is associated with manic morbidity in elderly patients with mood disorders","volume":"39","author":"Weiss","year":"2024","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1017\/S0033291724000345","article-title":"Neurocognitive correlates of metabolic dysregulation in individuals with mood disorders: A systematic review and meta-analysis","volume":"54","author":"Maksyutynska","year":"2024","journal-title":"Psychol. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/hbm.21268","article-title":"The obese brain: Association of body mass index and insulin sensitivity with resting state network functional connectivity","volume":"33","author":"Kullmann","year":"2011","journal-title":"Hum. Brain Mapp."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1590\/1516-4446-2020-1246","article-title":"Physical health in affective disorders: A narrative review of the literature","volume":"43","author":"Colomer","year":"2021","journal-title":"Rev. Bras. Psiquiatr."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Jones, B.D.M., Farooqui, S., Kloiber, S., Husain, M.O., Mulsant, B.H., and Husain, M.I. (2021). Targeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence. Life, 11.","DOI":"10.3390\/life11080819"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.2337\/dc12-1779","article-title":"Response to Comment on: Pan et al. Bidirectional Association Between Depression and Metabolic Syndrome: A Systematic Review and Meta-analysis of Epidemiological Studies. Diabetes Care 2012;35:1171\u20131180","volume":"36","author":"Pan","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4088\/JCP.13r08634","article-title":"Metabolic syndrome in bipolar disorder: A review with a focus on bipolar depression","volume":"75","author":"McElroy","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"ref_45","first-page":"166","article-title":"Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: A systematic review and large scale meta-analysis","volume":"15","author":"Vancampfort","year":"2016","journal-title":"World Psychiatry Off. J. World Psychiatr. Assoc. WPA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.4088\/JCP.v67n0704","article-title":"Associations between bipolar disorder and metabolic syndrome: A review","volume":"67","author":"Taylor","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1042\/CS20211106","article-title":"Severe psychiatric disorders and general medical comorbidities: Inflammation-related mechanisms and therapeutic opportunities","volume":"136","author":"Teixeira","year":"2022","journal-title":"Clin. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Qiu, W., Cai, X., Zheng, C., Qiu, S., Ke, H., and Huang, Y. (2021). Update on the Relationship Between Depression and Neuroendocrine Metabolism. Front. Neurosci., 15.","DOI":"10.3389\/fnins.2021.728810"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neubiorev.2018.05.014","article-title":"A review of brain insulin signaling in mood disorders: From biomarker to clinical target","volume":"92","author":"Nguyen","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"Correll","year":"2011","journal-title":"Trends Mol. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ando.2023.03.006","article-title":"Metabolic disorders induced by psychotropic drugs","volume":"84","author":"Scheen","year":"2023","journal-title":"Ann. Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms","volume":"125","author":"Gp","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"102581","DOI":"10.1016\/j.eclinm.2024.102581","article-title":"Effect of antipsychotics and mood stabilisers on metabolism in bipolar disorder: A network meta-analysis of randomised-controlled trials","volume":"71","author":"Kong","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0013-7006(14)70129-0","article-title":"Affective disorders: Endocrine and metabolic comorbidities","volume":"40","author":"Cermolacce","year":"2014","journal-title":"L\u2019Encephale"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mazereel, V., Detraux, J., Vancampfort, D., Van Winkel, R., and De Hert, M. (2020). Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.573479"},{"key":"ref_56","first-page":"180","article-title":"Metabolic syndrome and psychotropic medications","volume":"9","year":"2012","journal-title":"Med. Glas. Off. Publ. Med. Assoc. Zenica-Doboj Cant. Bosnia Herzeg."},{"key":"ref_57","first-page":"114","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"Detraux","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Yuen, J.W.Y., Kim, D.D., Procyshyn, R.M., Panenka, W.J., Honer, W.G., and Barr, A.M. (2021). A Focused Review of the Metabolic Side-Effects of Clozapine. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.609240"},{"key":"ref_59","first-page":"95","article-title":"Metabolic adverse drug reactions related to psychotropic drugs","volume":"93","author":"Gahr","year":"2025","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4088\/JCP.09r05346blu","article-title":"Antidepressants and body weight: A comprehensive review and meta-analysis","volume":"71","author":"Serretti","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Mukherjee, S., and Im, S.-S. (2025). Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus. Biomedicines, 13.","DOI":"10.3390\/biomedicines13020359"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Qassab, M.A., Mneimneh, M., Jradi, A., Derbas, B., Dabboussi, D., Baini, J.K., Katrib, N., Chaarani, N., Attieh, P., and Kanaan, A. (2025). The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47040285"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e70630","DOI":"10.1111\/jcmm.70630","article-title":"Exploring the Effect and Mechanism of Liraglutide in Treating Depression Based on Network Pharmacology and Experimental Analysis","volume":"29","author":"Sun","year":"2025","journal-title":"J. Cell Mol. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"101470","DOI":"10.1016\/j.diabet.2023.101470","article-title":"GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes","volume":"49","author":"Monney","year":"2023","journal-title":"Diabetes Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10354-011-0004-9","article-title":"Psychotropic drugs and diabetes","volume":"161","author":"Ress","year":"2011","journal-title":"Wien. Med. Wochenschr."},{"key":"ref_68","first-page":"330","article-title":"Can metabolic side effects of antipsychotics be reversed by lifestyle changes?","volume":"26","author":"Bolger","year":"2014","journal-title":"Psychiatr. Danub."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"106550","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000355632","article-title":"Unraveling the mechanisms responsible for the comorbidity between metabolic syndrome and mental health disorders","volume":"98","author":"Nousen","year":"2013","journal-title":"Neuroendocrinology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1172\/JCI78371","article-title":"Glucagon-like peptide-1 receptors in the brain: Controlling food intake and body weight","volume":"124","author":"Baggio","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"103029","DOI":"10.1016\/j.eclinm.2024.103029","article-title":"Suicide and suicide attempt in users of GLP-1 receptor agonists: A nationwide case-time-control study","volume":"80","author":"Bezin","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study","volume":"207","author":"Mansur","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/jamainternmed.2024.4369","article-title":"GLP-1 Receptor Agonist Use and Risk of Suicide Death","volume":"184","author":"Ueda","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","article-title":"GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: A crossover, randomised, placebo-controlled trial","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","article-title":"GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans","volume":"63","author":"IJzerman","year":"2014","journal-title":"Diabetes"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/osp4.124","article-title":"The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity","volume":"3","author":"Coveleskie","year":"2017","journal-title":"Obes. Sci. Pract."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","article-title":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model","volume":"71","author":"Zhang","year":"2018","journal-title":"Neuropeptides"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.psyneuen.2015.11.021","article-title":"GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality","volume":"65","author":"Anderberg","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","article-title":"The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors","volume":"32","author":"Dickson","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eplepsyres.2018.03.009","article-title":"Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus","volume":"142","author":"Wang","year":"2018","journal-title":"Epilepsy Res."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Gruber, J., Hanssen, R., Qubad, M., Bouzouina, A., Schack, V., Sochor, H., Schiweck, C., Aichholzer, M., Matura, S., and Slattery, D.A. (2023). Impact of insulin and insulin resistance on brain dopamine signalling and reward processing\u2014An underexplored mechanism in the pathophysiology of depression?. Neurosci. Biobehav. Rev., 149.","DOI":"10.1016\/j.neubiorev.2023.105179"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e18491","DOI":"10.1016\/j.heliyon.2023.e18491","article-title":"GLP-1 plays a protective role in hippocampal neuronal cells by activating cAMP-CREB-BDNF signaling pathway against CORT+HG-induced toxicity","volume":"9","author":"Ma","year":"2023","journal-title":"Heliyon"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"0300060521992981","DOI":"10.1177\/0300060521992981","article-title":"GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-\u03baB signalling pathway","volume":"49","author":"Chen","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/1753-0407.12891","article-title":"Effect of liraglutide on the Janus kinase\/signal transducer and transcription activator (JAK\/STAT) pathway in diabetic kidney disease in db\/db mice and in cultured endothelial cells","volume":"11","author":"Einbinder","year":"2019","journal-title":"J. Diabetes"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Li, Q., Lin, Y., Wang, S., Zhang, L., and Guo, L. (2017). GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-06712-z"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.brainres.2018.11.007","article-title":"Exendin-4 improves behaviorial deficits via GLP-1\/GLP-1R signaling following partial hepatectomy","volume":"1706","author":"Zhou","year":"2019","journal-title":"Brain Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"114053","DOI":"10.1016\/j.bbr.2022.114053","article-title":"The effect of glucagon like peptide-1 receptor agonist on behavioral despair and anxiety-like behavior in ovariectomized rats: Modulation of BDNF\/CREB, Nrf2 and lipocalin 2","volume":"435","author":"Turan","year":"2022","journal-title":"Behav. Brain Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11481-024-10142-w","article-title":"Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis","volume":"19","author":"Peixoto","year":"2024","journal-title":"J. Neuroimmune Pharmacol. Off. J. Soc. NeuroImmune Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jad.2019.05.044","article-title":"A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: Further link between metabolism and psychopathology: Special Section on \u201cTranslational and Neuroscience Studies in Affective Disorders\u201d. Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders","volume":"257","author":"Pozzi","year":"2019","journal-title":"J. Affect. Disord."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wakabayashi, K.T., Baindur, A.N., Feja, M., Suarez, M., Chen, K., Bernosky-Smith, K., and Bass, C.E. (2024). Synthetic exendin-4 disrupts responding to reward predictive incentive cues in male rats. Front. Behav. Neurosci., 18.","DOI":"10.3389\/fnbeh.2024.1363497"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Deden, L.N., Booij, J., Grandjean, J., Homberg, J.R., Hazebroek, E.J., Gotthardt, M., and Boss, M. (2021). Brain Imaging of the GLP-1 Receptor in Obesity Using 68Ga-NODAGA-Exendin-4 PET. Brain Sci., 11.","DOI":"10.3390\/brainsci11121647"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Tsai, C.-Y., Lu, H.-C., Chou, Y.-H., Liu, P.-Y., Chen, H.-Y., Huang, M.-C., Lin, C.-H., and Tsai, C.-N. (2022). Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.814770"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e17891","DOI":"10.7717\/peerj.17891","article-title":"Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice","volume":"12","author":"Feng","year":"2024","journal-title":"PeerJ"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"101590","DOI":"10.1016\/j.molmet.2022.101590","article-title":"GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein","volume":"65","author":"Hoffman","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41467-017-02488-y","article-title":"GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose","volume":"9","author":"Iwasaki","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Lindqvist, A., Shcherbina, L., Fischer, A.-H.T., and Wierup, N. (2017). Ghrelin Is a Regulator of Glucagon-Like Peptide 1 Secretion and Transcription in Mice. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00135"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e11128","DOI":"10.7717\/peerj.11128","article-title":"Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus","volume":"9","author":"Shang","year":"2021","journal-title":"PeerJ"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zeng, N., Cutts, E.J., Lopez, C.B., Kaur, S., Duran, M., Virkus, S.A., and Hardaway, J.A. (2021). Anatomical and Functional Characterization of Central Amygdala Glucagon-Like Peptide 1 Receptor Expressing Neurons. Front. Behav. Neurosci., 15.","DOI":"10.3389\/fnbeh.2021.724030"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/YCO.0000000000001001","article-title":"Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"38","author":"Almeida","year":"2025","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40501-022-00281-3","article-title":"Evaluating the Use of Glucagon-Like Peptide 1 for the Treatment of Cognitive Dysfunction in Individuals with Mood Disorders","volume":"9","author":"Gill","year":"2022","journal-title":"Curr. Treat. Options Psychiatry"},{"key":"ref_103","first-page":"24nr03828","article-title":"Efficacy of GLP-1 Agonists in Psychiatric Illnesses: A Scoping Review","volume":"27","author":"Ali","year":"2025","journal-title":"Prim. Care Companion CNS Disord."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"107312","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review\u2014Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target","volume":"207","author":"VI","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Xiang, L., and Peng, Y. (2025). Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062741"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11096-023-01694-7","article-title":"Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: A pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database","volume":"46","author":"Tobaiqy","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4093\/dmj.2025.0242","article-title":"Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab. J."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Reilly-Harrington, N.A., Himes, S.M., Lauretti-Robbins, J., and Sogg, S. One Size Does Not Fit All: Special Considerations for Behavioral Health Providers Treating Patients Using GLP-1RA Medications for Obesity. Cogn. Behav. Pract., 2025. in press.","DOI":"10.1016\/j.cbpra.2025.02.004"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/9\/1422\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:43:14Z","timestamp":1760035394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/9\/1422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":108,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["life15091422"],"URL":"https:\/\/doi.org\/10.3390\/life15091422","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}